PORTLAND, Ore. (KOIN) – The Trump administration announced Thursday that it struck deals with two major pharmaceutical manufacturers to make their popular weight loss products more affordable for Americans.

According to administration officials, Novo Nordisk and Lilly have agreed to sell their injectable GLP-1 products at a discounted rate for people on Medicare and Medicaid. The monthly starting price will be $245 for these drugs, known as Wegovy and Zepbound.

Trump’s officials claim to have made the agreement under the administration’s new Most Favored Nation (MFN) policy. However, Oregon Sen. Ron Wyden said the announcement was actually made possible through Medicare negotiations passed by Democrats.

“Medicare negotiated lower prices weeks ago, and rather than share those prices, Tru

See Full Page